Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-07-30
DOI
10.1111/dom.13484
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
- (2018) Kohei Kaku et al. DIABETES OBESITY & METABOLISM
- Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis
- (2018) Huilin Tang et al. DIABETES OBESITY & METABOLISM
- Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
- (2018) Tina Vilsbøll et al. DIABETES OBESITY & METABOLISM
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis
- (2017) P. Gargiulo et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
- (2017) Bo Ahrén et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
- (2017) Vanita R Aroda et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial
- (2016) L. Zang et al. DIABETES OBESITY & METABOLISM
- Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials
- (2016) Katherine R. Tuttle et al. DIABETES OBESITY & METABOLISM
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study
- (2015) E. Araki et al. DIABETES OBESITY & METABOLISM
- One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial
- (2015) S. C. L. Gough et al. DIABETES OBESITY & METABOLISM
- Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
- (2015) Xiang Wan et al. BMC Medical Research Methodology
- A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)
- (2014) C. Mathieu et al. DIABETES OBESITY & METABOLISM
- Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial
- (2014) Michaela Diamant et al. Lancet Diabetes & Endocrinology
- Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countries
- (2013) L. M. Ruta et al. DIABETIC MEDICINE
- Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
- (2012) M. Nauck et al. DIABETES OBESITY & METABOLISM
- One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
- (2011) R. Pratley et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes
- (2011) Kohei Kaku et al. Journal of Diabetes Investigation
- Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
- (2010) W. Yang et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
- (2010) A. Garber et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea
- (2009) Richard Bergenstal et al. CURRENT MEDICAL RESEARCH AND OPINION
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
- (2008) Gordon H Guyatt et al. BMJ-British Medical Journal
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search